Barely Significant
← all excerpts

Advances in immune checkpoint inhibitors for hepatocellular carcinoma.

J Liver Cancer · 2021 · PMC10035682 · PMID 37383085

Europe PMCDOI
1
hedged sentence
0.0420
closest p · 0.8× alpha
0.0420
boldest claim

The sentences

did not reach statistical significanceP =0.042actually significant
16 Unfortunately, the overall survival (OS) benefit of nivolumab compared to sorafenib did not reach statistical significance according to the pre-defined threshold in the trial design (HR, 0.84; P =0.042).

also in 45,344 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.